The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Current hurdles in developing CAR-T therapies for gastrointestinal tumors
Current hurdles in developing CAR-T therapies for gastrointestinal tumors
J. Randolph Hecht, MD, University of California, Los Angeles, CA, comments on remaining challenges in the field of CAR-T and cellular therapies for gastrointestinal malignancies. On-target, off-tumor toxicities remain an issue, where targets such as mesothelin are widespread in the body and are not necessarily tumor-specific. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
